Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia.
This study was planned to assess the response of anti-D in patients with immune thrombocytopenia (ITP). Twenty adults (8 males: 12 females) with a median age 33.5 years (19-59 years) were included. Nine patients had newly-diagnosed ITP, 6 had persistent ITP and 5 had chronic ITP. The overall response rate was 65%. Patients with newly diagnosed ITP showed response rates of 77% (7/9), persistent ITP had response rates 50% (3/6) and patients with chronic ITP had response rates of 60% (3/5). The median time to response was 3 days (1-11 days). There was no correlation of response with age, sex, severity of bleeding, presenting platelet counts, ABO blood group or prior steroid or IVIG response.
Department of Hematology, All India Institute of Medical Science, New Delhi, India. dr_rahul6@hotmail.com
Rahul
R
Naithani
Rajat
R
Kumar
M
M
Mahapatra
Seema
S
Tyagi
Renu
R
Saxena
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*; D055815:Young Adult
D018029:Rho(D) Immune Globulin